It's cheaper but it'll also be more accessible with more patients being able to afford treatment and it will also have a greater market share than Herceptin or Keytruda individually, after its paired with both of them (or any other biosimilar) that is. Bring on the licensing deals!
I don't think Roth would, but I reckon IMU definitely knows how much its costs to manufacture one injection.
I'm not even sure how Roth calculated 0.71c back in March 2021, but the fact it hasn't increased since yesterday's de-risking leaves me perplexed.
It's cheaper but it'll also be more accessible with more...
-
- There are more pages in this discussion • 137 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $404.2M | |||
| Open | High | Low | Value | Volume |
| 5.6¢ | 5.7¢ | 5.5¢ | $379.9K | 6.840M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 1581916 | 5.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.6¢ | 680013 | 6 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |